Literature DB >> 15725385

Human T cell epitope mapping of the Schistosoma mansoni 14-kDa fatty acid-binding protein using cells from patients living in areas endemic for schistosomiasis.

Cristina T Fonseca1, Edécio Cunha-Neto, Anna C Goldberg, Jorge Kalil, Amélia R de Jesus, Edgard M Carvalho, Rodrigo Correa-Oliveira, Sérgio C Oliveira.   

Abstract

The development of a defined anti-schistosomiasis vaccine would contribute to the current control strategy mainly because immunization provides long-lasting immunity to the disease. Sm14, one of the six Schistosoma mansoni antigens selected by WHO as a candidate to compose a subunit vaccine against schistosomiasis, has been associated with resistance to S. mansoni infection in human beings and is able to induce protection in the murine model. To identify human T cell epitopes in Sm14, we used the TEPITOPE algorithm to select peptides that would most likely bind to several HLA-DR molecules. In this study, three Sm14 epitopes were selected and produced as synthetic peptides. Human T cell responses from schistosomiasis patients living in endemic areas in Brazil were determined by proliferation assay and IL-5 and IFN-gamma measurements. Differential peptide recognition and cytokine production in response to Sm14 epitopes were observed in individuals resistant to S. mansoni infection versus susceptible individuals. Sm14(32-48) and Sm14(53-69) peptides were preferentially recognized by peripheral blood mononuclear cells (PBMCs) of S. mansoni-resistant individuals, and Sm14(53-69) induced significant production of IFN-gamma. Additionally, Sm14(32-48) and Sm14(53-69) were "promiscuous" peptides, since they were able to induce cellular immune responses in individuals carrying 10 and 8, respectively, of the 11 HLA-DR molecules expressed in the studied population. Among Sm14 synthetic peptides tested in this study, we identified Sm14(32-48) and Sm14(53-69) as promising candidates to compose an anti-schistosomiasis vaccine, since they seem to be related to resistance to human schistosomiasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15725385     DOI: 10.1016/j.micinf.2004.10.012

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  7 in total

1.  Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies.

Authors:  F C Cardoso; R N A Pacífico; R A Mortara; S C Oliveira
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

2.  Fasciola hepatica: identification of CD4+ T-helper epitopes from the 11.5 kDa saposin-like protein SAP-2 using synthetic peptides.

Authors:  Ana M Espino; Daricel Torres; Adelaida Morales; Bonnibel Delgado; Julia Quetel; Antonio Osuna
Journal:  Exp Parasitol       Date:  2007-03-27       Impact factor: 2.011

Review 3.  Current status of vaccines for schistosomiasis.

Authors:  Donald P McManus; Alex Loukas
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 4.  Eliminating Schistosomes through Vaccination: What are the Best Immune Weapons?

Authors:  Cristina Toscano Fonseca; Sergio Costa Oliveira; Clarice Carvalho Alves
Journal:  Front Immunol       Date:  2015-03-09       Impact factor: 7.561

Review 5.  Vaccines for Human Schistosomiasis: Recent Progress, New Developments and Future Prospects.

Authors:  Adebayo J Molehin; Donald P McManus; Hong You
Journal:  Int J Mol Sci       Date:  2022-02-18       Impact factor: 5.923

6.  Imatinib activity on Schistosoma mansoni.

Authors:  Naftale Katz; Flávia Fernanda Bubulo Couto; Neusa Araújo
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11       Impact factor: 2.743

7.  Predictions of novel Schistosoma mansoni - human protein interactions consistent with experimental data.

Authors:  J White Bear; Thavy Long; Danielle Skinner; James H McKerrow
Journal:  Sci Rep       Date:  2018-08-30       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.